- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01183013
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
A Randomised, Double-blind Parallel Group Study to Compare the Efficacy and Safety of Initial Combination Therapy With Linagliptin 5 mg + Pioglitazone 15 mg, 30 mg, or 45 mg, vs. Monotherapy With Pioglitazone (15 mg, 30 mg, or 45 mg) or Linagliptin 5 mg Once Daily for 30 Weeks, Followed by a Blinded Trial Period on Linagliptin 5 mg + Pioglitazone 30 or 45 mg Versus Pioglitazone Monotherapy 30 or 45 mg or Linagliptin 5 mg for up to 54 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control on Diet and Exercise
Přehled studie
Postavení
Podmínky
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
-
Harju, Estonsko
- 1264.3.37207 Boehringer Ingelheim Investigational Site
-
Pärnu, Estonsko
- 1264.3.37209 Boehringer Ingelheim Investigational Site
-
Tallin, Estonsko
- 1264.3.37203 Boehringer Ingelheim Investigational Site
-
Tallin, Estonsko
- 1264.3.37204 Boehringer Ingelheim Investigational Site
-
Tallin, Estonsko
- 1264.3.37205 Boehringer Ingelheim Investigational Site
-
Tallinn, Estonsko
- 1264.3.37201 Boehringer Ingelheim Investigational Site
-
Tallinn, Estonsko
- 1264.3.37202 Boehringer Ingelheim Investigational Site
-
Tallinn, Estonsko
- 1264.3.37208 Boehringer Ingelheim Investigational Site
-
Tartu, Estonsko
- 1264.3.37206 Boehringer Ingelheim Investigational Site
-
Viljandi County, Estonsko
- 1264.3.37210 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Daugavpils, Lotyšsko
- 1264.3.37105 Boehringer Ingelheim Investigational Site
-
Daugavpils, Lotyšsko
- 1264.3.37112 Boehringer Ingelheim Investigational Site
-
Daugavpils, Lotyšsko
- 1264.3.37113 Boehringer Ingelheim Investigational Site
-
Jelgava, Lotyšsko
- 1264.3.37110 Boehringer Ingelheim Investigational Site
-
Liepaja, Lotyšsko
- 1264.3.37101 Boehringer Ingelheim Investigational Site
-
Ogre, Lotyšsko
- 1264.3.37106 Boehringer Ingelheim Investigational Site
-
Riga, Lotyšsko
- 1264.3.37104 Boehringer Ingelheim Investigational Site
-
Riga, Lotyšsko
- 1264.3.37108 Boehringer Ingelheim Investigational Site
-
Riga, Lotyšsko
- 1264.3.37109 Boehringer Ingelheim Investigational Site
-
Riga, Lotyšsko
- 1264.3.37111 Boehringer Ingelheim Investigational Site
-
Talsi, Lotyšsko
- 1264.3.37107 Boehringer Ingelheim Investigational Site
-
Tukums, Lotyšsko
- 1264.3.37102 Boehringer Ingelheim Investigational Site
-
Valmiera, Lotyšsko
- 1264.3.37103 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bad Lauterberg / Harz, Německo
- 1264.3.49001 Boehringer Ingelheim Investigational Site
-
Dietzenbach, Německo
- 1264.3.49007 Boehringer Ingelheim Investigational Site
-
Dortmund, Německo
- 1264.3.49002 Boehringer Ingelheim Investigational Site
-
Essen, Německo
- 1264.3.49009 Boehringer Ingelheim Investigational Site
-
Hamburg, Německo
- 1264.3.49003 Boehringer Ingelheim Investigational Site
-
Ingelheim, Německo
- 1264.3.49012 Boehringer Ingelheim Investigational Site
-
Leipzig, Německo
- 1264.3.49008 Boehringer Ingelheim Investigational Site
-
Mainz, Německo
- 1264.3.49005 Boehringer Ingelheim Investigational Site
-
Offenbach, Německo
- 1264.3.49010 Boehringer Ingelheim Investigational Site
-
Stuhr, Německo
- 1264.3.49004 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Annan, Spojené království
- 1264.3.44032 Boehringer Ingelheim Investigational Site
-
Ash Vale, Aldershot, Spojené království
- 1264.3.44028 Boehringer Ingelheim Investigational Site
-
Baillieston, Glasgow, Spojené království
- 1264.3.44029 Boehringer Ingelheim Investigational Site
-
Balham, Spojené království
- 1264.3.44008 Boehringer Ingelheim Investigational Site
-
Bradford on Avon, Spojené království
- 1264.3.44021 Boehringer Ingelheim Investigational Site
-
Burbage, Spojené království
- 1264.3.44019 Boehringer Ingelheim Investigational Site
-
Chesterfield, Spojené království
- 1264.3.44012 Boehringer Ingelheim Investigational Site
-
Chestfield, Whitstable, Spojené království
- 1264.3.44027 Boehringer Ingelheim Investigational Site
-
Chippenham, Spojené království
- 1264.3.44011 Boehringer Ingelheim Investigational Site
-
Johnstone, Spojené království
- 1264.3.44033 Boehringer Ingelheim Investigational Site
-
Midsomer Norton, Spojené království
- 1264.3.44007 Boehringer Ingelheim Investigational Site
-
Paisley, Spojené království
- 1264.3.44034 Boehringer Ingelheim Investigational Site
-
Warminster, Spojené království
- 1264.3.44031 Boehringer Ingelheim Investigational Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Spojené státy
- 1264.3.01026 Boehringer Ingelheim Investigational Site
-
Montgomery, Alabama, Spojené státy
- 1264.3.01021 Boehringer Ingelheim Investigational Site
-
Muscle Shoals, Alabama, Spojené státy
- 1264.3.01020 Boehringer Ingelheim Investigational Site
-
-
Arizona
-
Chandler, Arizona, Spojené státy
- 1264.3.01062 Boehringer Ingelheim Investigational Site
-
Mesa, Arizona, Spojené státy
- 1264.3.01064 Boehringer Ingelheim Investigational Site
-
-
California
-
Carmichael, California, Spojené státy
- 1264.3.01049 Boehringer Ingelheim Investigational Site
-
Chino, California, Spojené státy
- 1264.3.01078 Boehringer Ingelheim Investigational Site
-
Concord, California, Spojené státy
- 1264.3.01031 Boehringer Ingelheim Investigational Site
-
Lakewood, California, Spojené státy
- 1264.3.01037 Boehringer Ingelheim Investigational Site
-
Los Angeles, California, Spojené státy
- 1264.3.01065 Boehringer Ingelheim Investigational Site
-
Norwalk, California, Spojené státy
- 1264.3.01006 Boehringer Ingelheim Investigational Site
-
Rancho Cucamonga, California, Spojené státy
- 1264.3.01001 Boehringer Ingelheim Investigational Site
-
San Diego, California, Spojené státy
- 1264.3.01059 Boehringer Ingelheim Investigational Site
-
Tarzana, California, Spojené státy
- 1264.3.01023 Boehringer Ingelheim Investigational Site
-
Tustin, California, Spojené státy
- 1264.3.01016 Boehringer Ingelheim Investigational Site
-
Valencia, California, Spojené státy
- 1264.3.01058 Boehringer Ingelheim Investigational Site
-
Westlake Village, California, Spojené státy
- 1264.3.01083 Boehringer Ingelheim Investigational Site
-
-
Colorado
-
Denver, Colorado, Spojené státy
- 1264.3.01027 Boehringer Ingelheim Investigational Site
-
-
Connecticut
-
Norwalk, Connecticut, Spojené státy
- 1264.3.01033 Boehringer Ingelheim Investigational Site
-
-
Florida
-
Boca Raton, Florida, Spojené státy
- 1264.3.01035 Boehringer Ingelheim Investigational Site
-
Clearwater, Florida, Spojené státy
- 1264.3.01015 Boehringer Ingelheim Investigational Site
-
Hialeah, Florida, Spojené státy
- 1264.3.01082 Boehringer Ingelheim Investigational Site
-
Jacksonville, Florida, Spojené státy
- 1264.3.01036 Boehringer Ingelheim Investigational Site
-
Longwood, Florida, Spojené státy
- 1264.3.01013 Boehringer Ingelheim Investigational Site
-
Miami, Florida, Spojené státy
- 1264.3.01038 Boehringer Ingelheim Investigational Site
-
Miami, Florida, Spojené státy
- 1264.3.01042 Boehringer Ingelheim Investigational Site
-
Miami, Florida, Spojené státy
- 1264.3.01079 Boehringer Ingelheim Investigational Site
-
Port Orange, Florida, Spojené státy
- 1264.3.01019 Boehringer Ingelheim Investigational Site
-
St. Cloud, Florida, Spojené státy
- 1264.3.01018 Boehringer Ingelheim Investigational Site
-
Tampa, Florida, Spojené státy
- 1264.3.01009 Boehringer Ingelheim Investigational Site
-
Tampa, Florida, Spojené státy
- 1264.3.01012 Boehringer Ingelheim Investigational Site
-
-
Georgia
-
Atlanta, Georgia, Spojené státy
- 1264.3.01008 Boehringer Ingelheim Investigational Site
-
Atlanta, Georgia, Spojené státy
- 1264.3.01055 Boehringer Ingelheim Investigational Site
-
Atlanta, Georgia, Spojené státy
- 1264.3.01061 Boehringer Ingelheim Investigational Site
-
Blue Ridge, Georgia, Spojené státy
- 1264.3.01074 Boehringer Ingelheim Investigational Site
-
Cartersville, Georgia, Spojené státy
- 1264.3.01084 Boehringer Ingelheim Investigational Site
-
Perry, Georgia, Spojené státy
- 1264.3.01060 Boehringer Ingelheim Investigational Site
-
Savannah, Georgia, Spojené státy
- 1264.3.01050 Boehringer Ingelheim Investigational Site
-
-
Illinois
-
Chicago, Illinois, Spojené státy
- 1264.3.01077 Boehringer Ingelheim Investigational Site
-
-
Indiana
-
Brownsburg, Indiana, Spojené státy
- 1264.3.01052 Boehringer Ingelheim Investigational Site
-
Evansville, Indiana, Spojené státy
- 1264.3.01075 Boehringer Ingelheim Investigational Site
-
Evansville, Indiana, Spojené státy
- 1264.3.01076 Boehringer Ingelheim Investigational Site
-
Franklin, Indiana, Spojené státy
- 1264.3.01073 Boehringer Ingelheim Investigational Site
-
-
Kansas
-
Wichita, Kansas, Spojené státy
- 1264.3.01002 Boehringer Ingelheim Investigational Site
-
Wichita, Kansas, Spojené státy
- 1264.3.01007 Boehringer Ingelheim Investigational Site
-
-
Kentucky
-
Lexington, Kentucky, Spojené státy
- 1264.3.01010 Boehringer Ingelheim Investigational Site
-
-
Louisiana
-
New Orleans, Louisiana, Spojené státy
- 1264.3.01028 Boehringer Ingelheim Investigational Site
-
Sunset, Louisiana, Spojené státy
- 1264.3.01029 Boehringer Ingelheim Investigational Site
-
-
Maryland
-
Hyattsville, Maryland, Spojené státy
- 1264.3.01069 Boehringer Ingelheim Investigational Site
-
-
Michigan
-
Southfield, Michigan, Spojené státy
- 1264.3.01066 Boehringer Ingelheim Investigational Site
-
-
Montana
-
Great Falls, Montana, Spojené státy
- 1264.3.01057 Boehringer Ingelheim Investigational Site
-
-
North Carolina
-
Burlington, North Carolina, Spojené státy
- 1264.3.01045 Boehringer Ingelheim Investigational Site
-
Charlotte, North Carolina, Spojené státy
- 1264.3.01044 Boehringer Ingelheim Investigational Site
-
-
Ohio
-
Zanesville, Ohio, Spojené státy
- 1264.3.01022 Boehringer Ingelheim Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy
- 1264.3.01032 Boehringer Ingelheim Investigational Site
-
-
Pennsylvania
-
Fleetwood, Pennsylvania, Spojené státy
- 1264.3.01051 Boehringer Ingelheim Investigational Site
-
Pittsburgh, Pennsylvania, Spojené státy
- 1264.3.01025 Boehringer Ingelheim Investigational Site
-
-
South Carolina
-
Columbia, South Carolina, Spojené státy
- 1264.3.01081 Boehringer Ingelheim Investigational Site
-
Greer, South Carolina, Spojené státy
- 1264.3.01003 Boehringer Ingelheim Investigational Site
-
-
Tennessee
-
Kingsport, Tennessee, Spojené státy
- 1264.3.01011 Boehringer Ingelheim Investigational Site
-
-
Texas
-
Corpus Christi, Texas, Spojené státy
- 1264.3.01017 Boehringer Ingelheim Investigational Site
-
Dallas, Texas, Spojené státy
- 1264.3.01067 Boehringer Ingelheim Investigational Site
-
Houston, Texas, Spojené státy
- 1264.3.01004 Boehringer Ingelheim Investigational Site
-
Houston, Texas, Spojené státy
- 1264.3.01039 Boehringer Ingelheim Investigational Site
-
Houston, Texas, Spojené státy
- 1264.3.01041 Boehringer Ingelheim Investigational Site
-
Houston, Texas, Spojené státy
- 1264.3.01047 Boehringer Ingelheim Investigational Site
-
Houston, Texas, Spojené státy
- 1264.3.01070 Boehringer Ingelheim Investigational Site
-
Killeen, Texas, Spojené státy
- 1264.3.01040 Boehringer Ingelheim Investigational Site
-
Midland, Texas, Spojené státy
- 1264.3.01048 Boehringer Ingelheim Investigational Site
-
New Braunfels, Texas, Spojené státy
- 1264.3.01030 Boehringer Ingelheim Investigational Site
-
North Richland Hills, Texas, Spojené státy
- 1264.3.01071 Boehringer Ingelheim Investigational Site
-
Plano, Texas, Spojené státy
- 1264.3.01085 Boehringer Ingelheim Investigational Site
-
San Antonio, Texas, Spojené státy
- 1264.3.01046 Boehringer Ingelheim Investigational Site
-
-
Virginia
-
Norfolk, Virginia, Spojené státy
- 1264.3.01056 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Badía del Vallès - Barcelona, Španělsko
- 1264.3.34013 Boehringer Ingelheim Investigational Site
-
Barcelona, Španělsko
- 1264.3.34001 Boehringer Ingelheim Investigational Site
-
Barcelona, Španělsko
- 1264.3.34008 Boehringer Ingelheim Investigational Site
-
Borges del Camp- Tarragona, Španělsko
- 1264.3.34005 Boehringer Ingelheim Investigational Site
-
Canet de Mar - Barcelona, Španělsko
- 1264.3.34006 Boehringer Ingelheim Investigational Site
-
Centelles - Barcelona, Španělsko
- 1264.3.34010 Boehringer Ingelheim Investigational Site
-
L'Hospitalet de Llobregat, Španělsko
- 1264.3.34009 Boehringer Ingelheim Investigational Site
-
L'Hospitalet de Llobregat - Barcelona, Španělsko
- 1264.3.34004 Boehringer Ingelheim Investigational Site
-
Sant Adrià del Besós- Barcelona, Španělsko
- 1264.3.34002 Boehringer Ingelheim Investigational Site
-
Tarrega - Lleida, Španělsko
- 1264.3.34007 Boehringer Ingelheim Investigational Site
-
Valencia, Španělsko
- 1264.3.34012 Boehringer Ingelheim Investigational Site
-
Vic - Barcelona, Španělsko
- 1264.3.34011 Boehringer Ingelheim Investigational Site
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion criteria:
- Diagnosis of type 2 diabetes mellitus prior to informed consent
- Male and female patients with insufficient glycaemic control (HbA1c >= 7.0 to <= 10.5% at Visit 2) on diet and exercise alone, without oral antidiabetic drug therapy within 10 weeks prior to start of the run-in period (date of Visit 2)
- Age >= 18 and <= 80 years at start date of Visit 1 (Screening)
- BMI <= 45 kg/m2 (Body Mass Index) at start date of Visit 1 (Screening)
- Signed and dated written informed consent by start date of Visit 1 in accordance with GCP and local legislation
Exclusion criteria:
- Uncontrolled hyperglycaemia with a confirmed glucose level > 240 mg/dl (> 13.3 mmol/l) after an overnight fast during screening or placebo run-in period (cf. Section 3.3.4.1)
- Myocardial infarction within 6 months, stroke or TIA within 3 months prior to informed consent
- Clinical evidence of active liver disease (e.g. jaundice) or the ALT level > 2.5 times the upper limit of normal (according to pioglitazone label)
- Bariatric surgery, performed within the past 2 years prior to informed consent or planned at the time of informed consent
- Gastrointestinal surgeries prior to informed consent that induce chronic malabsorption
- Known hypersensitivity or allergy to the investigational products (linagliptin and/or pioglitazone) or their excipients (including matching placebos)
Contraindications to pioglitazone as defined in the local prescribing information (SPC), particularly :
- Diagnose of heart failure or history of heart failure
- Haemodialysis patients, due to limited experience with pioglitazone
- Treatment with gemfibrozil, montelukast, trimethoprim, or rifampicin - according to pioglitazone label and respective restrictions in Section 4.2.2
- Treatment with rosiglitazone, pioglitazone, GLP-1 analogues, or insulin within 3 months prior to informed consent
- Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to informed consent
- Alcohol or drug abuse within the 3 months prior to informed consent or history of alcoholism
- Current treatment with systemic corticosteroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent
- Participation in another trial with an investigational drug within 30 days prior to informed consent
- Any other clinical condition as judged by the investigator that would not allow the safe completion of the protocol, e.g. inability of patients to comply with study procedures
Pre-menopausal women (last menstruation <= 1 year prior to informed consent) who:
- are nursing or pregnant or
- are of child-bearing potential (i.e. not permanently sterilised) and are not practicing a highly effective method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial.
A highly effective method of birth control is defined - according to the Note for Guidance on non-clinical safety studies for the conduct of human trials for pharmaceuticals (CPMP/ICH/286/95, modification) - as those which result in a low failure rate (i. e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, hormonal intrauterine devices/systems (IUDs/IUSs), sexual abstinence or vasectomised partner
- Symptomatic gallbladder disease in the last six months
- Medical history of pancreatitis.
- Patients with urinary bladder cancer or a history of urinary bladder cancer or uninvestigated macroscopic haematuria
- Any other contraindication or restriction for use of pioglitazone in accordance with the local prescribing information for pioglitazone.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Aktivní komparátor: Pioglitazone 15 mg
Pioglitazone Capsules 15 mg once daily
|
Pioglitazone Capsules 15 mg once daily for 30 weeks followed by Pioglitazone Capsules 30 mg once daily for up to 54 weeks
|
Aktivní komparátor: Pioglitazone 30 mg
Pioglitazone Capsules 30 mg once daily
|
Pioglitazone Capsules 30 mg once daily for up to 84 weeks
|
Aktivní komparátor: Pioglitazone 45 mg
Pioglitazone Capsules 45 mg once daily
|
Pioglitazone Capsules 30 mg once daily for 6 weeks followed by Pioglitazone Capsules 45 mg once daily for up to 78 weeks
|
Aktivní komparátor: Linagliptin 5mg
Linagliptin 5mg Tablets once daily
|
Linagliptin 5mg Tablets low dose once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
|
Experimentální: Linagliptin 5mg / Pioglitazone 15 mg
Linagliptin 5mg / Pioglitazone 15 mg Tablets once daily
|
Linagliptin 5mg low dose / Pioglitazone 15 mg FDC Tablets once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
|
Experimentální: Linagliptin 5mg / Pioglitazone 30 mg
Linagliptin 5mg / Pioglitazone 30 mg Tablets once daily
|
Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 84 weeks
|
Experimentální: Linagliptin 5mg / Pioglitazone 45 mg
Linagliptin 5mg / Pioglitazone 45 mg Tablets once daily
|
Linagliptin 5mg low dose / Pioglitazone 30 mg Tablets once daily for 6 weeks followed by Linagliptin 5mg low dose / Pioglitazone 45 mg FDC Tablets once daily for up to 78 weeks
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Change From Baseline in HbA1c After 30 Weeks of Treatment.
Časové okno: Baseline and 30 weeks
|
HbA1c is measured as a percentage.
The change from baseline is the Week 30 HbA1c minus the baseline HbA1c.
|
Baseline and 30 weeks
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Occurrence of Cumulative Treat to Target Efficacy Response, of HbA1c Under Treatment of < 7.0% After 30 Weeks of Treatment
Časové okno: Baseline and 30 weeks
|
Glycosylated hemoglobin is reported as a percentage of the total hemoglobin.
|
Baseline and 30 weeks
|
Occurrence of Cumulative Treat to Target Efficacy Response, of HbA1c Under Treatment of < 6.5% After 30 Weeks of Treatment
Časové okno: Baseline and 30 weeks
|
Glycosylated hemoglobin is reported as a percentage of the total hemoglobin.
|
Baseline and 30 weeks
|
Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 30 Weeks of Treatment)
Časové okno: Baseline and 30 weeks
|
Glycosylated hemoglobin is reported as a percentage of the total hemoglobin.
|
Baseline and 30 weeks
|
HbA1c Change From Baseline by Visit Over Time
Časové okno: Baseline, week 6, week 12, week 18, week 24, week 30
|
HbA1c is measured as a percentage. The change from baseline is the HbA1c over time minus the baseline HbA1c. The model includes fixed effects for treatment, continuous baseline HbA1c, prior andi-diabetic medication, country, visit and treatment. by visit interaction. |
Baseline, week 6, week 12, week 18, week 24, week 30
|
Fasting Plasma Glucose (FPG) Change From Baseline After 30 Weeks of Treatment
Časové okno: Baseline and 30 weeks
|
The change from baseline is the FPG after 30 weeks minus the baseline FPG.
|
Baseline and 30 weeks
|
Fasting Plasma Glucose (FPG) Change From Baseline by Visit Over Time
Časové okno: Baseline, week 6, week 12, week 18, week 24, week 30
|
The change from baseline is the FPG over time minus the baseline FPG.
Model includes fixed effects for treatment, continuous baseline FPG, continuous baseline HbA1c, prior anti-diabetic medication, country, visit and treatment by visit interaction
|
Baseline, week 6, week 12, week 18, week 24, week 30
|
Two-hour Postprandial Glucose (2hPPG) Change From Baseline at Week 30 by Meal Tolerance Test (MTT)
Časové okno: Baseline and 30 weeks
|
The change from baseline is the 2hPPG after 30 weeks minus the baseline 2hPPG.
|
Baseline and 30 weeks
|
Time to First Use of Rescue Therapy
Časové okno: 30 weeks
|
Proportion of patients at 30 weeks with rescue therapy using Kaplan-Meier analysis.
|
30 weeks
|
Incidence of Rescue Therapy During the First 30 Weeks of Treatment
Časové okno: 30 weeks
|
Rescue therapy was defined to include any new antidiabetic medication taken for hyperglycemia and introduced on or after the start date of study treatment and before the end date of study treatment.
|
30 weeks
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Publikace a užitečné odkazy
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Poruchy metabolismu glukózy
- Metabolické choroby
- Onemocnění endokrinního systému
- Diabetes Mellitus
- Diabetes mellitus, typ 2
- Hypoglykemická činidla
- Fyziologické účinky léků
- Molekulární mechanismy farmakologického působení
- Inhibitory enzymů
- Hormony
- Hormony, hormonální náhražky a antagonisté hormonů
- Inhibitory proteázy
- Inkretiny
- Inhibitory dipeptidyl-peptidázy IV
- Pioglitazon
- Linagliptin
Další identifikační čísla studie
- 1264.3
- 2008-008127-15 (Číslo EudraCT: EudraCT)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Diabetes mellitus, typ 2
-
Hoffmann-La RocheDokončenoDiabetes 2. typu, Diabetes 1. typuRakousko, Spojené království
-
Services Hospital, LahoreDokončeno
-
Griffin HospitalCalifornia Walnut CommissionDokončenoDIABETES MELLITUS TYP 2Spojené státy
-
West China HospitalDokončeno
-
University of Roma La SapienzaNeznámýDiabetes Mellitus Typ 2 Reaktivita krevních destiček StatinItálie
-
Bristol-Myers SquibbDokončenoDiabetes, typ 2Spojené státy, Kanada, Mexiko, Portoriko, Austrálie, Polsko, Tchaj-wan
-
Universidade Federal de Ouro PretoDokončeno
-
Kyowa Kirin Co., Ltd.Dokončeno
-
Novo Nordisk A/SNáborDiabetes, typ 2Spojené státy, Indie, Španělsko, Polsko, Jižní Afrika, Bulharsko, Německo, Japonsko, Portoriko
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Churchill HospitalDokončenoDiabetes, typ 2Spojené království
Klinické studie na Pioglitazone 15 mg
-
University at BuffaloTakeda Pharmaceuticals North America, Inc.Dokončeno
-
West Virginia UniversityNáborRakovina prsu | Svalová únavaSpojené státy
-
Seung Up KimAktivní, ne náborDiabetes mellitus, typ 2 | Hepatitida B, chronická | Fibróza, játraKorejská republika
-
University of Maryland, BaltimoreNico CorporationNáborIntracerebrální krvácení, intraventrikulárníSpojené státy
-
Chong Kun Dang PharmaceuticalDokončenoDiabetes mellitus 2. typuKorejská republika
-
Boryung Pharmaceutical Co., LtdDokončeno
-
Mansoura UniversityDokončenoCML, chronická fáze | Chronická myeloidní leukémie, BCR-ABL pozitivníEgypt
-
United States Army Research Institute of Environmental...DokončenoVysoká nadmořská výškaSpojené státy
-
Madrigal Pharmaceuticals, Inc.Dokončeno
-
Huashan HospitalBaxter Healthcare CorporationDokončenoZánět | Rezistence na inzulín | Peritoneální dialýza | Hypertriglyceridémie | Pioglitazon